Blockbuster weight-loss drug supply hit in trade shutdown

Blockbuster weight-loss drug supply hit in trade shutdown

An Eli Lilly & Co. Zepbound injection pen, March 28, 2024. Bloomberg | Bloomberg | Getty Images As a port strike stretching from New England to Texas halted nearly half of all trade coming into the U.S., customs data shows that critical medical devices and drug components for the booming, expensive weight-loss and diabetes drugs … Read more

CVS is working with advisors on strategic review, sources say

CVS is working with advisors on strategic review, sources say

CVS Pharmacy logo is seen in Washington DC, United States on July 9, 2024.  Jakub Porzycki | Nurphoto | Getty Images CVS Health‘s board has engaged advisors to conduct a strategic review of its business, according to people familiar with the matter, as the company contends with potential activist pressure and a severely depressed stock … Read more

Major CVS shareholder plans activist push, meet with execs: sources

Major CVS shareholder plans activist push, meet with execs: sources

CVS Pharmacy logo is seen at store in Florida Keys, United States on May 7, 2024.  Jakub Porzycki | Nurphoto | Getty Images Glenview Capital, a major CVS Health shareholder, is expected to meet with company leadership on Monday to lay out proposed fixes for the struggling business, according to people familiar with the matter, … Read more

FDA approves Bristol Myers Squibb’s schizophrenia drug

FDA approves Bristol Myers Squibb’s schizophrenia drug

Bristol Myers Squibb’s Cobenfy drug Courtesy: Bristol Myers Squibb The Food and Drug Administration on Thursday approved Bristol Myers Squibb‘s highly anticipated schizophrenia drug Cobenfy, the first novel type of treatment for the debilitating, chronic mental disorder in more than seven decades.  Schizophrenia affects how a person thinks, feels and behaves, and can cause paranoia, … Read more

Novo Nordisk’s Ozempic may lower risk of opioid overdoses: study

Novo Nordisk’s Ozempic may lower risk of opioid overdoses: study

A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters Novo Nordisk‘s blockbuster diabetes drug Ozempic may decrease the risk of opioid overdoses in certain patients, demonstrating its potential as an alternative treatment for opioid use disorder, according to a new study … Read more

Novo Nordisk CEO to testify at Senate over weight loss drug prices

Novo Nordisk CEO to testify at Senate over weight loss drug prices

Lars Fruergaard Jørgensen, CEO of Novo Nordisk, speaks during an interview in New York on Aug. 10, 2022. Christopher Goodney | Bloomberg | Getty Images Novo Nordisk‘s top executive is slated to face a Senate grilling on Tuesday over the high prices of the company’s weight loss drug Wegovy and diabetes treatment Ozempic, as demand … Read more

Why Eli Lilly and Palo Alto Networks are both up on news from their competitors

Why Eli Lilly and Palo Alto Networks are both up on news from their competitors

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: The Dow and S & P 500 were lower Friday after surging to record highs Thursday in response to the Fed cutting interest rates by … Read more

FTC sues drug middlemen for allegedly inflating insulin prices

FTC sues drug middlemen for allegedly inflating insulin prices

Lina Khan, Chair of the Federal Trade Commission (FTC), testifies before the House Appropriations Subcommittee at the Rayburn House Office Building on May 15, 2024 in Washington, DC.  Kevin Dietsch | Getty Images News | Getty Images The Federal Trade Commission on Friday sued three large U.S. health companies that negotiate insulin prices, arguing the … Read more

Novartis not joining the ‘frenzy’ of weight loss drugs, CEO says

Novartis not joining the ‘frenzy’ of weight loss drugs, CEO says

The CEO of Novartis said Wednesday that the Swiss pharmaceutical giant does not plan to enter into the “frenzy” of weight loss drugs, preferring instead to focus on areas where it can build a “unique position.” Speaking to CNBC, Vas Narasimhan said that the company was researching treatments that deal with the secondary effects of … Read more

Pfizer’s cancer cachexia drug shows positive midstage trial results

Pfizer’s cancer cachexia drug shows positive midstage trial results

Pfizer‘s experimental drug for a common, life-threatening condition that causes cancer patients to lose their appetite and weight showed positive results in a midstage trial, the drugmaker said Saturday.  Patients with the condition, called cancer cachexia, who took Pfizer’s treatment saw improvements in body weight, muscle mass, quality of life and physical function, according to … Read more